Catalyzing the Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalyzing the Synthesis
Researchers develop various catalytic approaches for improving yield, purity, stereoselectivity, and process conditions.


Pharmaceutical Technology
pp. 44-50

Making acids behave like bases

A research team lead by Guy Bertrand, a distinguished professor of chemistry at the University of California at Riverside, recently reported on the use of boron-based compounds to build Lewis bases.

The researchers reported on the synthesis and characterization of a neutral tricoordinate organoboron isoelectronic with amines. The neutral tricoordinate boron derivative acted as a Lewis base and underwent one-electron oxidation into the corresponding radical cation. These compounds were the parent borylene and borinylium, respectively, stabilized by two cyclic (alkyl)(amino) carbenes. Ab initio calculations showed that the highest occupied molecular orbital of the borane and the singly occupied molecular orbital of the radical cation were essentially a pair and a single electron, respectively, in the p(p) orbital of boron (7).

"The result is totally counterintuitive," said Bertrand, in an July 28, 2011, University of California at Riverside press release. "...But we have achieved it. We have transformed boron compounds into nitrogen-like compounds. In other words, we have made acids behave like bases."

Nitrogen- or phosphorus-based compounds are commonly used as ligands in catalysts. "The trouble with using phosphorus-based catalysts is that phosphorus is toxic and it can contaminate the end products," Bertrand said. "Our work shows that it is now possible to replace phosphorus ligands in catalysts with boron ligands. And boron is not toxic," he added. Researchers at Philipps–Universitat in Marburg, Germany, also contributed to the study.

References

1. J.N.H. Reek et. al., J. Am. Chem. Soc., online DOI: 10.1021/ja208589, Sept. 30, 2011.

2. S. Ritter, Chem. & Eng. News 89 (42), 13 (2011).

3. J.M. John and S.H. Bergens, Angew. Chem. Int. Ed. 50 (44), 10377–10380 (2011).

4. K.C. Harper and M.S. Singer, Science 333 (6051), 1875–1878 (2011).

5. F. Meyer nd C. Limber, eds., "Preface" in Organometallic Oxidation Catalysis (Springer, New York, 2007).

6. J.T. Yates, Jr., et al., Science 333 (6043), 736–739 (2011).

7. G. Bertrand, Science 333 (6042), 610–613 (2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here